Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 150-152
DOI: 10.4103/ijmpo.ijmpo_113_18
Practitioner Section

Methotrexate and mucositis: A merry-go-round for oncologists

Kundan Mishra
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Aditya Jandial
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Anil Kumar
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Deepesh Lad
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Gaurav Prakash
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Alka Khadwal
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Pankaj Malhotra
Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

High-dose methotrexate is the backbone of various regimens for treating lymphoid malignancies. Mucositis is a well-known, dose-related side effect of methotrexate. Prophylactic measures such as folinic acid rescue are useful but do not prevent mucositis in all the cases. Once severe mucositis (WHO Grade IV) sets in, mortality is very high. The index case highlights the natural course of methotrexate-induced mucositis and the need for swift and preemptive intervention.

Keywords

Lymphoid malignancy - methotrexate - mucositis


Publication History

Article published online:
08 June 2021

© 2019. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238: 787-93
    CrossrefPubMedGoogle Scholar
  • 2 Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist 2016; 21: 1471-82
    CrossrefPubMedGoogle Scholar
  • 3 Rask C, Albertioni F, Schrøder H, Peterson C. ral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: Relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996; 13: 359-67
    CrossrefPubMedGoogle Scholar
  • 4 Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M. et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025
    CrossrefPubMedGoogle Scholar
  • 5 Goldin A, Venditti JM, Kline I, Mantel N. Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966; 212: 1548-50
    CrossrefPubMedGoogle Scholar
  • 6 Schmidt S, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM. et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol 2008; 19: 1644-9
    CrossrefPubMedGoogle Scholar
  • 7 Schwartz S, Borner K, Müller K, Martus P, Fischer L, Korfel A. et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12: 1299-308
    CrossrefPubMedGoogle Scholar
  • 8 Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A. et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 2018; 23: 52-61
    CrossrefPubMedGoogle Scholar
  • 9 Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM. et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-61
    CrossrefPubMedGoogle Scholar